ESMO 2024

ESMO 2024
September 13-17, 2024
Barcelona, Spain

European Society of Medical Oncology Congress 2024 .

Explore more information for Gilead Oncology therapies
Material Type
Filter by Keyword(s)

Filter results with keywords such as:

  • Name of author(s)
  • Disease state
  • Indication
  • Trial phase
  • Trial name
  • Trial date

Note: Multiple keywords can be applied at the same time.

    Results (5)

    Efficacy and safety of sacituzumab govitecan in patients with advanced/metastatic endometrial cancer: updated results from TROPiCS-03

    • Author(s): Corr, B
    • trodelvy
    • Oncology
    • TROPiCs-03
    • endomedtiral cancer
    • EC
    • Sacituzumab
    • SG
    • Trodelvy

    Quality-adjusted Time Without Symptoms of disease progression or Toxicity of treatment (Q-TWiST) analysis to assess benefit-risk of sacituzumab govitecan in previously treated patients with metastatic triple-negative breast cancer

    • Author(s): Brufsky, A
    • trodelvy
    • Oncology
    • Sacituzumab
    • SG
    • Trodelvy
    • TNBC

    Patient-reported outcomes (PROs) from the phase 3 EVOKE-01 trial of sacituzumab govitecan (SG) vs docetaxel (doc) in metastatic non-small cell lung cancer (mNSCLC)

    • Author(s): Reinmuth, N
    • trodelvy
    • Oncology
    • SG
    • Sacituzumab
    • Trodelvy
    • NSCLC
    • PD-L1 High
    • Lung

    Real-World Treatment Patterns and Sequencing in Locally Advanced or Metastatic Urothelial Carcinoma Patients Receiving Sacituzumab Govitecan in the United States

    • Author(s): Mamtani, R
    • trodelvy
    • Oncology
    • Sacituzumab
    • SG
    • Trodelvy
    • Urothelial
    • mUC
    • RWE
    • Real world

    Exploratory circulating tumor DNA analysis in HR+/HER2- metastatic breast cancer and impact on clinical efficacy with Sacituzumab Govitecan in TROPiCS-02

    • Author(s): Rugo, HS
    • trodelvy
    • Oncology
    • TROPiCS-02
    • HR+/HER2-
    • HR+
    • Sacituzumab
    • SG
    • Trodelvy